A randomised, double-blind, crossover, dose ranging study to determine the optimal dose of oral opioid to treat breakthrough pain for patients with advanced cancer already established on regular opioids

COMMENTED

Cancer PainPain Management

Regular dosing compared with as needed dosing of opioids for management of chronic cancer pain: systematic review and meta-analysis

★ 3 Recommended and commented by Dr Roland Schreiber, Faculty Member

doi: 10.1097/j.pain.0000000000001755.

Chronic Pain

Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic non-cancer pain: a randomized, double-blind, placebo-controlled phase 3 study

Pain.

Webster LR, Nalamachu S, Morlion B, Reddy J, Baba Y, Yamada T, Arjona Ferreira JC

doi: 10.1097/

Cancer Pain

Breakthrough pain is not a fixed fraction of constant cancer pain

Eur J Pain.

Klepstad P, Thronaes M, Torbjørn Løhre E

doi: 10.1002/ejp.1566.

Cancer Pain

Factors influencing the use of opioids for breakthrough cancer pain: a secondary analysis of the IOPS-MS study

Eur J Pain.

Mercadante S, Adile C, Masedu F, Marchetti P, Costanzi A, Aielli F

doi: 10.1002/ejp.1339.

Cancer Pain

Pain Intensity Factors Changing Breakthrough Pain Prevalence in Patients with Advanced Cancer: A Secondary Analysis of a Cross-Sectional Observational International Study

Pain Ther.

Løhre ET, Hjermstad MJ, Brunelli C, Knudsen AK, Kaasa S, Klepstad P

doi: 10.1007/s40122-018-0107-8.

Cancer Pain

Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study

J Clin Med.

Mercadante S, Masedu F, Valenti M, Aielli F

doi: 10.3390/jcm9051337.

Cancer Pain

Prospective Association of Serum Opioid Levels and Clinical Outcomes in Patients With Cancer Pain Treated With Intrathecal Opioid Therapy

Anesth Analg.

Brogan SE, Sindt JE, Jackman CM, White J, Wilding V, Okifuji A

doi: 10.1213/ANE.

COMMENTED

Cancer Pain

Effect of opioid exposure on efficacy and tolerability of sublingual fentanyl and subcutaneous morphine for severe cancer pain episodes. Secondary analysis from a double-blind double-dummy, randomized trial

J Pain Symptom Manage.

Ricchini F, Caraceni A, Zecca E, Pigni A, Centurioni F, Manzoni A, Kaasa S, Brunelli C

doi: 10.1016/

Back Pain

Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain

J Pain Res.

Webster LR, Israel RJ

doi: 10.2147/JPR.S160488.

Related content

Regular dosing compared with as needed dosing of opioids for management of chronic cancer pain: systematic review and meta-analysis

Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic non-cancer pain: a randomized, double-blind, placebo-controlled phase 3 study

Breakthrough pain is not a fixed fraction of constant cancer pain

Factors influencing the use of opioids for breakthrough cancer pain: a secondary analysis of the IOPS-MS study

Pain Intensity Factors Changing Breakthrough Pain Prevalence in Patients with Advanced Cancer: A Secondary Analysis of a Cross-Sectional Observational International Study

Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study

Prospective Association of Serum Opioid Levels and Clinical Outcomes in Patients With Cancer Pain Treated With Intrathecal Opioid Therapy

Effect of opioid exposure on efficacy and tolerability of sublingual fentanyl and subcutaneous morphine for severe cancer pain episodes. Secondary analysis from a double-blind double-dummy, randomized trial

Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain